The correlations between symptom improvement, general health and the number of weeks of treatment with Milmed mean that complete treatments are required for optimal therapeutic benefits. As previously observed, 10 to 14 weeks of treatment with MILMED™ provides a distinct improvement in allergy symptoms and enhanced general health.
Starting 2008, research has been ongoing in Sweden with Professor Trevor Archer as head of research. Uppsala University, Linnaeus University in Kalmar and the University of Gothenburg have been important partners along the way. Since 2016, Milmed has also collaborated with the research university Sapenzia in Rome with Professor Rita Businaro as research leader.
The effects of our patented treatment of the yeast, Saccharomyces cerevisiae, bioactive yeast cells with probiotic properties, have previously shown neuroprotective and neurorestorative properties on allergies. This was presented by a group of patients, who were compared with a matched group of patients that were given untreated yeast cells.
Treated yeast cells were subjected to millimeter-wave exposure as described in patent documents. In addition to the patients in the study reporting clear improvements in their allergic symptoms, they also (self) assessed that their general health condition improved significantly. The patients assigned to untreated yeast cells did not report similar improvements.
Trevor has published nearly a thousand scientific articles during his long career and the most recent regarding Milmed in the Journal of Immunology and Allergy February 2020 and November 2020. This was after conducting an allergy study in 2018 with positive results on improvements for allergic disorders. Over 85% were fully recovered or markedly better. The study constituted the core for a patent application filed in 2019 which led to, in October 2020, The Company having an approved patent for treatment of allergic disorders. Allergic disorders are the largest disease group in the entire western world. (WAO).
Since 2008 we have performed over 20 preclinical studies and our synopsis for a Phase I clinical trial is now ready. As mentioned, all our treatment areas fit into one Phase I clinical trial and the first treatment area we will put through Phase II is the treatment of inflammatory diseases. Our product for treatment of allergic disorders will, in 2023, be available as a dietary supplement under the name Alnozine TM and can be ordered at www.alnozine.com in January 2023.